Prelude Therapeutics
Market cap $266M 80.1M shares (10-Q, Nov 11, 2026) × $3.32 close Nov 17, 2026
Most recent annual filing: 2026-03-10
- mCALR DAC corporate updateBy year-end 2026mCALR DAC corporate update, By year-end 2026, routine
- PRLD corporate updateNov 2026PRLD corporate update, Nov 2026, routine
- Incyte JAK2V617F next-gen readoutDec 2026Incyte JAK2V617F next-gen readout, Dec 2026, material
- JAK2V617F program Incyte option partnership2027JAK2V617F program Incyte option partnership, 2027, material
- PRT12396 Ph1 interim2027PRT12396 Ph1 interim, 2027, notable
- PRLD shelf registration financingMay 2027PRLD shelf registration financing, May 2027, routine
- Pfizer prifetrastat topline~2H 2027Pfizer prifetrastat topline, ~2H 2027, major
- Menarini MEN2312 Ph1 readout~Oct 2027Menarini MEN2312 Ph1 readout, ~Oct 2027, notable
- PRLD corporate financing2Q 2028PRLD corporate financing, 2Q 2028, routine
- PRT12396 Ph1 readout~Apr 30, 2028PRT12396 Ph1 readout, ~Apr 30, 2028, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
PRT13722
Technology platforms
DAC · AbCellera Biologics
Degrader Antibody Conjugate platform combining targeted protein degrader payloads (including SMARCA2/4 dual degraders) with antibodies targeting tumor-specific antigens; focus areas include myeloproliferative neoplasms (mutant CALR-expressing cells) and solid tumors with SMARCA4 mutations. In collaboration with AbCellera for up to five programs (joint discovery, development, commercialization); AbCellera also independently developing select DACs under a non-exclusive degrader payload license.
Targets: SMARCA2, SMARCA4, CALR
Degrader Antibody Conjugates · AbCellera
Proprietary degrader payload-linker platform for degrader antibody conjugates (DACs); payloads include SMARCA2/4 dual degraders (VHL- and CRBN-based) and CDK9 degraders; engineered for improved efficacy, tolerability, and developability vs. traditional cytotoxic ADC payloads; applicable across oncology indications including myeloproliferative neoplasms; payloads available for licensing to partners developing next-generation DACs.
Targets: SMARCA2, SMARCA4, CDK9, mCALR
Precision ADC Degrader Payload · AbCellera
Degrader payload platform for antibody-drug conjugates (ADCs), engineering targeted protein degraders (TPDs) as prodrug payloads with high potency and cell-line selectivity, designed for improved efficacy and tolerability over traditional cytotoxic payloads; focus areas include oncology across solid tumors and hematologic cancers
Targets: SMARCA2, SMARCA4
DAC degrader payloads · AbCellera Biologics
Next-generation degrader antibody conjugate (DAC) platform leveraging targeted protein degradation expertise; highly potent SMARCA2/4 and CDK9 degrader payloads optimized for efficacy, tolerability and developability; also developing mutant CALR (mCALR)-targeted DACs for myeloid malignancies including myelofibrosis and essential thrombocythemia
Targets: SMARCA2, SMARCA4, CDK9, mCALR
DAC · AbCellera
Degrader Antibody Conjugate platform combining proprietary SMARCA2/4 dual degrader payloads with tumor antigen-targeting antibodies; focus areas include CALR-mutant myeloproliferative neoplasms and SMARCA4-mutant cancers. Co-developed with AbCellera Biologics for up to five programs.
Targets: SMARCA2, SMARCA4, CALR
Discontinued (3)
- PRT3789 — undisclosed · paused clinical development; resources prioritized to JAK2V617F and KAT6A programs
- PRT7732 — Non-Small Cell Lung Cancer · paused clinical development; resources prioritized to JAK2V617F and KAT6A programs
- PRT811 — undisclosed · out-licensed exclusively to Pathos AI; company retains only milestone/royalty economics
Capital (as filed)
- Cash
- $23.4M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $117M Sep 30, 2026
- Operating cash flow
- −$13.8M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $143M cash, runway the second quarter of 2028 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (2)
- 2026-11-17 UPDATE: Prelude Therapeutics (PRLD) - Lilly Lends the Backbone 🔒 Paid
- 2026-10-02 Prelude Therapeutics (PRLD) - Scientific Deep Dive for PRT13722, PRT12396 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (2 calls)
Every verdict Biotech Distilled has published on Prelude Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-10-02 Watch Prelude Therapeutics (PRLD) - Scientific Deep Dive for PRT13722, PRT12396 and Pipeline Products Pfizer has validated the KAT6 target but Prelude's key differentiator—KAT6A-selective degradation safe enough to combine with CDK4/6 inhibitors—has no human data, and the preclinical case relies on racemate and tool-compound evidence; the two decisive facts (Incyte option decision and first PRT13722 neutrophil counts) are 4–12 months away.
- 2026-11-17 Watch UPDATE: Prelude Therapeutics (PRLD) - Lilly Lends the Backbone The Lilly supply deal puts the CDK4/6 combination on the calendar and cash came in ahead of estimate, but no patient neutrophil data exist and the Incyte option decision remains pending, so the watch stance is unchanged.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Pending clearance of the IND application, we expect the Phase 1 study of PRT13722 in HR+ breast cancer to be initiated in the fourth quarter of 2026.”
matched to PRT13722 · trial initiation
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (23)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Oct 13, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026ReleasePrelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- Nov 16, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1→ BD updatePrelude confirmed first patients dosed with PRT13722 in Q4 2026 and signed Eli Lilly to supply abemaciclib and imlunestrant for the Phase 1 combination cohorts — directly addressing the combinability hypothesis that was the entire bull case in the prior writeup.
- Nov 16, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 16, 2026ReleasePrelude Therapeutics to Participate in the Chardan Healthcare Conference
- Oct 13, 2026ReleasePrelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Brea
- Sep 10, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Aug 11, 20268-KCurrent report: results of operations · EX-99.1
- Aug 11, 202610-QQuarterly report
- Jun 10, 20268-KCurrent report: shareholder vote
- May 12, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- May 12, 202610-QQuarterly report
- Apr 29, 2026DEFA14AProxy soliciting material
- Apr 29, 2026DEF 14AProxy statement
- Apr 23, 2026SCHEDULE 13D/A13D amendment
- Apr 22, 2026SCHEDULE 13D/A13D amendment
- Apr 21, 20268-KCurrent report: material agreement, other events · EX-99.1
- Apr 21, 2026424B5Prospectus supplement (offering)
- Apr 20, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Apr 15, 20268-KCurrent report: officer / director change · EX-99.1
- Mar 12, 20268-KCurrent report: other events
- Mar 12, 2026424B5Prospectus supplement (offering)
- Mar 10, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- Mar 10, 202610-KAnnual report
4 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Jul 8, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 29, 2026ARSAnnual report to shareholders
- Apr 28, 2026SCHEDULE 13GPassive >5% holder (13G)
- Mar 10, 2026S-8Employee plan registration